What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature

[1] Adams ME(1993)Viscosupplementation: a treatment for osteoarthritis J Rheum 20 2-1840

[2] Bellamy N(1988)Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 15 1833-802

[3] Buchanan WW(1997)Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III J Rheumatol 24 799-306

[4] Goldsmith CH(2004)Intra articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study Clin Exp Rheumatol 22 300-242

[5] Bellamy N(1993)Use of sodium hyaluronate in treating temporo-mandibular joint disorders: a randomized double blind, placebo controlled clinical trial J Oral Maxillofacial Surg 51 232-3330

[6] Kirwan J(1994)A pilot clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid Clin Ther Res 55 3319-391

[7] Boers M(2002)Hip osteoarthritis: short term efficacy and safety of viscosupplementation by hylan G-F 20. An open label study in 22 patients Joint Bone Spine 69 388-344

[8] Berg P(2005)Safety and efficacy of ultrasound-guided intra-articular hylan G-F 20 injection in osteoarthritis of the hip: a pilot study Rheumatol Int 25 341-610

[9] Olsson U(1999)Septic hip arthritis after multiple injections into the joint of hyaluronate and glucocorticoid Rev Rhum (Engl Ed) 6 436-716

[10] Bertolami C(2003)Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open label multicentre, pilot study Clin Exp Rheumatol 21 605-419

[1] Adams ME(1993)Viscosupplementation: a treatment for osteoarthritis J Rheum 20 2-1840

[2] Bellamy N(1988)Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 15 1833-802

[3] Buchanan WW(1997)Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III J Rheumatol 24 799-306

[4] Goldsmith CH(2004)Intra articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study Clin Exp Rheumatol 22 300-242

[5] Bellamy N(1993)Use of sodium hyaluronate in treating temporo-mandibular joint disorders: a randomized double blind, placebo controlled clinical trial J Oral Maxillofacial Surg 51 232-3330

[6] Kirwan J(1994)A pilot clinical evaluation of the treatment of hip osteoarthritis with hyaluronic acid Clin Ther Res 55 3319-391

[7] Boers M(2002)Hip osteoarthritis: short term efficacy and safety of viscosupplementation by hylan G-F 20. An open label study in 22 patients Joint Bone Spine 69 388-344

[8] Berg P(2005)Safety and efficacy of ultrasound-guided intra-articular hylan G-F 20 injection in osteoarthritis of the hip: a pilot study Rheumatol Int 25 341-610

[9] Olsson U(1999)Septic hip arthritis after multiple injections into the joint of hyaluronate and glucocorticoid Rev Rhum (Engl Ed) 6 436-716

[10] Bertolami C(2003)Intra-articular injections of hylan G-F 20 in patients with symptomatic hip osteoarthritis: an open label multicentre, pilot study Clin Exp Rheumatol 21 605-419